2011/12/15: Sygnis Pharma AG

SYGNIS Pharma AG (Frankfurt: LIOK; ISIN DE000A1E9B74; Prime Standard) today announces key results of the Phase II clinical trial (AXIS 2) of AX200 to treat acute ischemic stroke.


2011/12/14: Wilex AG

WILEX AG (ISIN DE0006614720 / WL6 / Frankfurt Stock Exchange) and IBA (Ion Beam Applications S.A: Reuters IBAB.BR and Bloomberg IBAB.BB) today announced that


2011/12/07: Agennix AG

Agennix AG (Frankfurt Stock Exchange (Prime Standard): AGX/ISIN DE000A1A6XX4) today announced


2011/12/07: Wilex AG

WILEX Inc., a wholly owned US subsidiary of WILEX AG (ISIN DE0006614720 / WL6 / Frankfurt Stock Exchange), today announced


2011/11/25: Sygnis Pharma AG

At today’s Annual General Meeting (AGM) of SYGNIS Pharma AG (Frankfurt: LIOK; ISIN DE000A1E9B74; Prime Standard) share-holders representing


2011/11/21: Wilex AG

WILEX AG (ISIN DE0006614720 / WL6 / Frankfurt Stock Exchange) today announced that the IDMC has recommended


2011/11/16: Agennix AG

Agennix AG (Frankfurt Stock Exchange (Prime Standard): AGX/ISIN DE000A1A6XX4) today announced that its Management Board has resolved, with the approval of the Supervisory Board


2011/11/16: Agennix AG

Agennix AG (Frankfurt Stock Exchange: AGX) today announced that the Company will give a presentation at the upcoming German Equity Forum (Eigenkapitalforum) in Frankfurt, Germany.


2011/11/15: CureVac GmbH

CureVac, Sanofi Pasteur and In-Cell-Art collaborate on a $33.1 million  project co-funded by the U.S. Defense Advanced Research Projects Agency


2011/11/14: Sygnis Pharma AG

SYGNIS Pharma AG (Frankfurt: LIOK; ISIN DE000A1E9B74; Prime Standard) today reports its financial results for the second quarter and the first half of the fiscal year 2011/2012 ended September 30, 2011


2011/11/07: CureVac GmbH

CureVac presents results of a Phase I/IIa trial in non-small cell lung cancer with CV9201, an mRNA based cancer vaccine, at the 26th Annual SITC Meeting in Washington


2011/11/03: Sygnis Pharma AG

SYGNIS  Pharma  AG  (Frankfurt:  LIOK;  ISIN DE000A1E9B74;  Prime  Standard),  a  clinical  stage  biotech  company  researching  and developing  innovative  CNS  treatments


2011/11/03: Agennix AG

Agennix AG (Frankfurt Stock Exchange: AGX), a biopharmaceutical company focused on developing novel therapies that


2011/11/02: joimax GmbH

For the first time, joimax® presents a comprehensive product offering for endoscopic spinal surgery, showing the novel pain therapy product “Multiuse”.


2011/10/20: joimax GmbH

The Society for Minimally Invasive Spine Surgery Announces Agreement With joimax® To Support Creation and Launch of SMISS Registry for Endoscopic Spine Surgery


2011/10/19: joimax GmbH

joimax® Launches Numerous Innovations at EuroSpine Milan From 19 To 21 October 2011


2011/10/14: Wilex AG

WILEX AG (ISIN DE0006614720 / Frankfurt Stock Exchange / Prime Standard) today announced that


2011/10/13: Wilex AG

WILEX AG (ISIN DE0006614720 / WL6 / Frankfurt Stock Exchange) today published its financial report for the first nine months of the 2011 financial year


2011/10/11: Agennix AG

Agennix Announces Data from Talactoferrin Phase II Trial in Non-Small Cell Lung Cancer Published in Journal of Clinical Oncology


2011/10/10: Wilex AG

WILEX AG (ISIN DE0006614720 / WL6 / Frankfurt Stock Exchange) today announced that


2011/10/06: joimax GmbH

joimax® inspires Thai-German Neurosurgery Congress participants for TESSYS®


2011/10/05: Wilex AG

WILEX AG (ISIN DE0006614720 / WL6 / Frankfurt Stock Exchange) announced  today


2011/09/20: Apogenix AG

Apogenix Successfully Completes Patient Recruitment for Glioblastoma Phase II Trial with APG101


2011/09/15: Sygnis Pharma AG

SYGNIS Pharma AG (Frankfurt: LIOK; ISIN DE000A1E9B74; Prime Standard), a clinical stage biotech company researching and developing innovative therapies for neurodegenerative diseases, today announced that the European Patent Office has given two notices


2011/09/15: Wilex AG

Munich, 15 September 2011. WILEX AG (ISIN DE0006614720 / WL6 / Frankfurt Stock Exchange) announced today the start of another Phase I trial


2011/09/12: Agennix AG

Agennix AG (Frankfurt Stock Exchange (Prime Standard): AGX) today announced


2011/08/11: Sygnis Pharma AG

SYGNIS Pharma AG (Frankfurt: LIOK; ISIN DE000A1E9B74; Prime Standard) today reports its financial results for the first quarter of the fiscal year 2011/2012


2011/08/10: Sygnis Pharma AG

The shareholders of SYGNIS Pharma AG (Frankfurt: LIOK; ISIN DE000A1E9B74; Prime Standard) exercised their


2011/08/10: Agennix AG

Agennix Announces Issuance of European Patent Covering Use of Talactoferrin to Treat Cancer


2011/08/09: Syngis Pharma AG

SYGNIS Pharma AG (Frankfurt: LIOK; ISIN DE000A1E9B74; Prime Standard), a clinical stage biotech company researching and developing innovative CNS treatments, announced that both


2011/08/09: Syngis Pharma AG

SYGNIS Pharma AG (Frankfurt: LIOK; ISIN DE000A1E9B74; Prime Standard), a clinical stage biotech company researching and developing innovative CNS treatments, announced the successful completion of the patient recruitment


2011/08/04: Agennix AG

Agennix Reports Financial Results for Second Quarter and First Six Months of 2011


2011/08/03: Wilex AG

WILEX’s subsidiary WILEX Inc. receives ISO certification


2011/07/25: Agennix AG

Agennix Schedules Conference Call on August 4 to Discuss Second Quarter of 2011 Financial Results


2011/07/20: Agennix AG

Agennix Hires Christine Boisclair as Senior Vice President of Global Regulatory Affairs


2011/07/15: Novaliq GmbH

Novaliq receives € 2.3 million funding


2011/07/14: Wilex AG

WILEX announces successful half year results


2011/07/05: Agennix AG

Agennix Announces Data from Talactoferrin Phase II Trial in Severe Sepsis Presented at World Conference on Cancer


2011/07/04: Cytonet GmbH & Co. KG

Dedicated employees, creative inquiry and above all the courage to dare to venture into largely ‘undeveloped ground’ of medicine have brought this medium-sized enterprise to the top – to a position on the list of Germany’s 100 top innovators


2011/06/30: Agennix AG

Agennix Initiates Phase II/III OASIS Trial with Talactoferrin Severe Sepsis


2011/06/22: Agennix AG

Agennix Hires Jill Porter as Senior Vice President of Pharmaceutical Development


2011/06/20: joimax GmbH

joimax® sets the second highlight in its anniversary year: The TESSYS®/iLESSYS® User Meeting in Heidelberg


2011/06/17: Wilex AG

WILEX and IBA report on the Pre-BLA Meeting with the FDA and the next steps in the REDECTANE® approval process


2011/06/15: immatics GmbH

First patients are vaccinated in IMPRINT*, immatics’ pivotal Phase III trial with IMA901 in patients with renal cell carcinoma (RCC)


2011/06/10: CureVac GmbH

CureVac presents promising new data for prostate cancer vaccine CV9103 and
lung cancer vaccine CV9201 at the ASCO Conference


2011/06/05: Agennix AG

Agennix Announces New Data from Talactoferrin Phase II Trials in Non-Small Cell Lung Cancer and in Severe Sepsis Presented at ASCO Annual Meeting


2011/06/01: Agennix AG

Agennix AG Announces Talactoferrin Data to be Presented at ASCO 2011 Annual Meeting


2011/05/31: Cosmo Pharmaceuticals S.p.A.

COSMO ANNOUNCES FILING OF BUDESONIDE MMX® FOR TREATMENT OF MILD TO MODERATE ACTIVE ULCERATIVE COLITIS IN EUROPE


2001/05/24: Cytonet GmbH & Co. KG

International biotechnology firm Cytonet, which is investigating a liver cell infusion of donated human liver cells for the treatment of urea cycle disorders (UCD) in young children


2011/05/18: Agennix AG

New Data from Talactoferrin Phase II Trial in Severe Sepsis Presented at American Thoracic Society International Conference


2011/05/09: AC Immune SA

AC Immune receives significant milestone payment from Genentech
Start of Phase II trial of anti-Abeta antibody for Alzheimer’s Disease.


2011/05/05: Wilex AG

Patient recruitment in Phase II breast cancer trial with MESUPRON® successfully completed.


2011/05/05:Sygnis Pharma AG

SYGNIS strengthens its KIBRA-Project: first Patents announced for Europe and the USA


2011/05/05: Agennix AG

Agennix Announces New Data from Talactoferrin Phase II Trials in Non-Small Cell Lung Cancer and
in Severe Sepsis Presented at ASCO Annual Meeting


2011/05/04: Agennix AG

Agennix AG Reports Financial Results for First Quarter of 2011


2011/05/02: Wilex AG

WILEX grants exclusive US commercialisation rights for RENCAREX® to Prometheus


2011/04/28: Agennix AG

Agennix AG Schedules Conference Call on May 4, 2011 to Discuss First Quarter 2011 Financial
Results


2011/04/22: AC Immune SA

Sequence-independent control of peptide conformation in liposomal vaccines for targeting protein misfolding diseases


2011/04/15: Agennix AG

Agennix AG Appoints New Vice President of Clinical Development


2011/04/15: LIFE Biosystems AG

Life Biosystems Developing In Silico Toolkit for Personalizing Oncology Therapy


2011/04/13: Cytonet GmbH & Co. KG

International biotechnology firm Cytonet recently launched the first ever clinical trial in the United States using an investigational liver cell infusion to treat urea cycle disorders (UCD) in children


2011/04/13: Wilex AG

WILEX publishes financial report for the first quarter of 2011


2011/04/11: immatics GmbH

immatics to receive support from Pfizer for its pivotal Phase III study (IMPRINT) with IMA901, a therapeutic vaccine for advanced renal cell cancer patients.


2011/04/10: joimax GmbH

joimax® for the first time awards the Parviz Kambin prize in cooperation with SMISS in the frame
of the first US TESSYS® User Meeting in Denver, Colorado.


2011/03/31: LIFE Biosystems AG

LIFE Biosystems Presents New Platform to Analyze Molecular Basis of Drug Side Effects in Patients

LIFE Biosystems Presents New ESA Findings at AACR Annual Meeting


2011/03/28: Curacyte AG

PHOENIX Phase III trial of PHP for distributive shock to continue after positive midpoint recommendation from DMB


2011/03/25: Cosmo Pharmaceuticals S.p.A.

Cosmo reports good 2010 operational results
-- Strategic goals met - Confident outlook for 2011 --


2011/03/23: Agennix AG

Agennix AG Announces Issuance of U.S. Patent Covering Use of Talactoferrin to Treat Non-Small Cell Lung Cancer and Renal Cell Carcinoma


2011/03/22: Sygnis Pharma AG

SYGNIS enters final stage with its Phase II efficacy study of AX200 for the treatment of acute stroke


2011/03/22: Agennix AG

Agennix AG to Participate in 4th Kempen & Co Healthcare/Life Sciences Conference


2011/03/16: Agennix AG

Agennix AG Announces Completion of Enrollment in Talactoferrin Phase III FORTIS-M Trial in Non-Small Cell Lung Cancer

Agennix AG Reports Financial Results For Fiscal Year 2010


2011/03/14: Novaliq GmbH

DIETMAR HOPP JOINS NOVALIQ GMBH, A COMPANY BELONGING TO THE GEUDER GROUP BASED
IN HEIDELBERG, GERMANY.


2011/03/04: Agennix AG

Agennix AG Announces Changes to Management Board and Supervisory Board


2011/03/01: immatics GmbH

immatics appoints Dr. Harald Stock to its Board


2011/02/22: Wilex AG

WILEX reports on the successful financial year 2010


2011/02/16: Cytonet GmbH & Co. KG

Liver Cell Therapy in Children with Urea Cycle Defect


2011/01/26: Agennix AG

Agennix AG to Present at Two Investor Conferences in February


2011/01/24: Apogenix GmbH

Apogenix provides update in the ongoing Phase II clinical trial of
APG101 to treat Glioblastoma
Data Safety Monitoring Board recommends continuation of
patient recruitment


2011/01/17: Agennix AG

Agennix AG Announces Longer-Term Mortality Data from Talactoferrin Phase II Trial in Severe Sepsis Presented at 40th Critical Care Congress